Using cardiac MRI to study healthy women for heart disease insights
Official title: Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing - Ancillary Study to Coronary Endothelial Function and Microvascular Disease in Women
Run by Cedars-Sinai Medical Center · NCT00573339 · Data updated 2026-11-12
This study is testing how cardiac MRI can help us learn more about heart health in healthy women to improve diagnosis and treatment for women with small artery heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 35 Years to 65 Years |
| Sex | Women only |
| Enrollment | 20 (estimated) |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | May 2007 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | September 1, 2023 |
| Trial ID | NCT00573339 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy women without any signs or symptoms of heart disease.
✕Probably not a fit
Patients with existing heart disease or those who do not meet the inclusion criteria will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research aims to apply cardiac magnetic resonance imaging (CMR) to women without heart disease to establish a normal reference control group. The study will enroll 40 healthy women who will undergo various assessments, including exercise treadmill tests and CMR scans, to gather data on cardiovascular health. By comparing these results to those of women with small artery heart disease, the study seeks to enhance understanding of CMR's utility in diagnosing and treating this condition. The findings may lead to improved noninvasive diagnostic techniques for women suffering from small vessel heart disease.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic methods for small artery heart disease in women, potentially improving treatment outcomes.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in using advanced imaging techniques for cardiovascular assessment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women without signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing). 2. No cardiac risk factors by Framingham/NCEP criteria, age and BMI matched to the Cardiac Syndrome X population, and a normal exercise stress test. Exclusion Criteria: 1. Contraindications to CMR testing (metal devices in chest, claustrophobia, known angioedema). 2. Contraindication to Adenosine or Lexiscan (regadenoson) including heart block (second and third degree) and sinus node disease, significant COPD/asthma, or systemic hypotension (\<90 mmHg). 3. Contraindication to Dobutamine including severe systemic hypertension (≥ 220/120 mmHg), unstable angina, significant aortic valve stenosis, complex cardiac arrhythmia including uncontrolled atrial fibrillation, hypertrophic obstructive cardiomyopathy, myocarditis, endocarditis, pericarditis, or uncontrolled congestive heart failure. 4. Contraindication to Gadolinium (renal impairment). 5. Any renal disease. 6. Pregnant and lactating women. 7. Inability to perform exercise, eg. orthopedic limitations. 8. Allergy to animal dander.
Where it's running
-
Cedars-Sinai Women's Heart Center
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: C. Noel Bairey Merz, MD — Cedars-Sinai Medical Center
- Study coordinator: Nicole Tovar
- Email: nicole.tovar@cshs.org
- Phone: 310-248-6960
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.